Lentinan Prolonged Survival in Patients with Gastric Cancer Receiving S-1-based Chemotherapy

Overview

Journal World J Clin Oncol

Publisher Baishideng Publishing Group

Specialty Oncology

Date 2011 Oct 14

PMID 21994907

Citations 20

Authors

Kenji Ina

Ryuichi Furuta

Takae Kataoka

Satoshi Kayukawa

Takashi Yoshida

Takaya Miwa

Yoshitaka Yamamura

Yuuki Takeuchi

Affiliations

Soon will be listed here.

Abstract

Aim: To examine whether administration of lentinan, purified β-1, 3-glucan, can prolong survival in advanced gastric cancer patients receiving S-1-based chemotherapy.

Methods: Since 2004, 78 patients with metastatic or recurrent gastric cancer have received S-1-based chemotherapy as first-line treatment. Survival, side effects, and the ratio of granulocytes/lymphocytes (G/L ratio) were compared between 2 groups of patients who received chemo-immunotherapy using lentinan and chemotherapy alone.

Results: Median overall survival was significantly longer in the former group than in the latter group [689 d (95% CI: 431-2339 d) vs 565 d (95% CI: 323-662 d), P = 0.0406]. In addition, the G/L ratio in patients who received lentinan was maintained around or below 2, which was significantly lower than that in patients who received chemotherapy alone (P < 0.001).

Conclusion: Chemo-immunotherapy with lentinan offers a significant advantage over S-1-based chemotherapy alone in terms of survival in patients with advanced gastric cancer.

Citing Articles

Research Progress of Immunotherapy for Gastric Cancer.

Zhang Z, Liu N, Sun M Technol Cancer Res Treat. 2023; 22:15330338221150555.

PMID: 37042029 PMC: 10102952. DOI: 10.1177/15330338221150555.

Theranostic Cancer Treatment Using Lentinan-Coated Selenium Nanoparticles and Label-Free CEST MRI.

Liu G, Ling J, He L, Xu Y, Chen T, Shi C Pharmaceutics. 2023; 15(1).

PMID: 36678748 PMC: 9864256. DOI: 10.3390/pharmaceutics15010120.

Synthesis of bioactive (1→6)-β-glucose branched poly-amido-saccharides that stimulate and induce M1 polarization in macrophages.

Xiao R, Zeng J, Bressler E, Lu W, Grinstaff M Nat Commun. 2022; 13(1):4661.

PMID: 35945224 PMC: 9363418. DOI: 10.1038/s41467-022-32346-5.

How Should the Worldwide Knowledge of Traditional Cancer Healing Be Integrated with Herbs and Mushrooms into Modern Molecular Pharmacology?.

Kirdeeva Y, Fedorova O, Daks A, Barlev N, Shuvalov O Pharmaceuticals (Basel). 2022; 15(7).

PMID: 35890166 PMC: 9320176. DOI: 10.3390/ph15070868.

Immunoregulatory activity of a low-molecular-weight heteropolysaccharide from fruiting bodies and .

Gao X, Zeng R, Qi J, Ho C, Li B, Chen Z Food Chem X. 2022; 14:100321.

PMID: 35571333 PMC: 9092982. DOI: 10.1016/j.fochx.2022.100321.

References

Sastre J, Garcia-Saenz J, Diaz-Rubio E . Chemotherapy for gastric cancer. World J Gastroenterol. 2006; 12(2):204-13. PMC: 4066028. DOI: 10.3748/wjg.v12.i2.204. View

Scanlon K, Newman E, Lu Y, Priest D . Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci U S A. 1986; 83(23):8923-5. PMC: 387045. DOI: 10.1073/pnas.83.23.8923. View

Sulkes A, Smyth J, Sessa C, Dirix L, Vermorken J, Kaye S . Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group. Br J Cancer. 1994; 70(2):380-3. PMC: 2033505. DOI: 10.1038/bjc.1994.310. View

Hamuro J, Rollinghoff M, Wagner H . beta(1 leads to 3) Glucan-mediated augmentation of alloreactive murine cytotoxic T-lymphocytes in vivo. Cancer Res. 1978; 38(9):3080-5. View

Ina K, Furuta R, Kataoka T, Nishio T, Nagao S, Kayukawa S . [Two advanced gastric cancer cases with peritoneal metastases successfully treated by s-1/paclitaxel combination therapy]. Gan To Kagaku Ryoho. 2009; 36(6):979-81. View

Narahara H, Fujitani K, Takiuchi H, Sugimoto N, Inoue K, Uedo N . Phase II study of a combination of S-1 and paclitaxel in patients with unresectable or metastatic gastric cancer. Oncology. 2008; 74(1-2):37-41. DOI: 10.1159/000138978. View

Oba K, Kobayashi M, Matsui T, Kodera Y, Sakamoto J . Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer. Anticancer Res. 2009; 29(7):2739-45. View

Iwase H, Shimada M, Tsuzuki T, Ina K, Sugihara M, Haruta J . A phase II multi-center study of triple therapy with paclitaxel, S-1 and cisplatin in patients with advanced gastric cancer. Oncology. 2011; 80(1-2):76-83. DOI: 10.1159/000328746. View

Sakamoto J, Teramukai S, Nakazato H, Sato Y, Uchino J, Taguchi T . Efficacy of adjuvant immunochemotherapy with OK-432 for patients with curatively resected gastric cancer: a meta-analysis of centrally randomized controlled clinical trials. J Immunother. 2002; 25(5):405-12. DOI: 10.1097/00002371-200209000-00004. View

10.

Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, Kumada K . A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group. Hepatogastroenterology. 1999; 46(28):2662-8. View

11.

Ohtsu A, Boku N, Tamura F, Muro K, Shimada Y, Saigenji K . An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. Am J Clin Oncol. 1998; 21(4):416-9. DOI: 10.1097/00000421-199808000-00021. View

12.

Kubota E, Kataoka H, Hayashi K, Kamiya T, Sasaki M, Ogasawara N . Advanced stomach and pancreas cancer successfully treated with combination chemotherapy with S-1/paclitaxel/lentinan. Hepatogastroenterology. 2009; 56(89):106-10. View

13.

Yoshino S, Tabata T, Hazama S, Iizuka N, Yamamoto K, Hirayama M . Immunoregulatory effects of the antitumor polysaccharide lentinan on Th1/Th2 balance in patients with digestive cancers. Anticancer Res. 2001; 20(6C):4707-11. View

14.

Ina K, Kataoka T, Takeuchi Y, Fukuoka T, Miwa T, Nishio T . Pathological complete response induced by the combination therapy of S-1 and 24-h infusion of cisplatin in two cases initially diagnosed as inoperable advanced gastric cancer. Oncol Rep. 2008; 20(2):259-64. View

15.

Iwase H, Shimada M, Tsuzuki T, Horiuchi Y, Kumada S, Haruta J . A phase II multicentric trial of S-1 combined with 24 h-infusion of cisplatin in patients with advanced gastric cancer. Anticancer Res. 2005; 25(2B):1297-301. View

16.

Brown G, Gordon S . Immune recognition. A new receptor for beta-glucans. Nature. 2001; 413(6851):36-7. DOI: 10.1038/35092620. View

17.

Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J . Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet. 1994; 343(8906):1122-6. DOI: 10.1016/s0140-6736(94)90233-x. View

18.

Nimura H, Mitsumori N, Takahashi N, Kashimura H, Takayama S, Kashiwagi H . [S-1 combined with lentinan in patients with unresectable or recurrent gastric cancer]. Gan To Kagaku Ryoho. 2006; 33 Suppl 1:106-9. View

19.

Vetvicka V . Glucan-immunostimulant, adjuvant, potential drug. World J Clin Oncol. 2011; 2(2):115-9. PMC: 3095473. DOI: 10.5306/wjco.v2.i2.115. View

20.

Takeda K, Kaisho T, Akira S . Toll-like receptors. Annu Rev Immunol. 2003; 21:335-76. DOI: 10.1146/annurev.immunol.21.120601.141126. View